NKTR-214
Phase 1/2Completed 0 watching 0 views this week๐ค Quiet
36
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unspecified Adult Solid Tumor, Protocol Specific
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Trial Timeline
Dec 1, 2015 โ Oct 31, 2018
NCT ID
NCT02869295About NKTR-214
NKTR-214 is a phase 1/2 stage product being developed by Nektar Therapeutics for Unspecified Adult Solid Tumor, Protocol Specific. The current trial status is completed. This product is registered under clinical trial identifier NCT02869295. Target conditions include Unspecified Adult Solid Tumor, Protocol Specific.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02869295 | Phase 1/2 | Completed |
Competing Products
20 competing products in Unspecified Adult Solid Tumor, Protocol Specific
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DJ-927 + capecitabine | Daiichi Sankyo | Phase 1 | 33 |
| E7389 + E7389 + E7389 | Eisai | Phase 1 | 33 |
| bevacizumab + enzastaurin hydrochloride | Eli Lilly | Phase 1 | 33 |
| SHR-1916 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| PI3K inhibitor BKM120 + docetaxel | Novartis | Phase 1 | 33 |
| bevacizumab + cyclophosphamide + imatinib | Novartis | Phase 1 | 33 |
| capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev) | Novartis | Phase 1 | 33 |
| warfarin | Novartis | Phase 1 | 33 |
| RLY-1971 | Roche | Phase 1 | 33 |
| Domvanalimab + Zimberelimab | Gilead Sciences | Phase 1 | 32 |
| BEZ235 + MEK162 | Pfizer | Phase 1 | 32 |
| Utomilumab + ISA101b | Pfizer | Phase 2 | 51 |
| Irinotecan | Pfizer | Phase 1 | 32 |
| Ixabepilone + Sunitinib | Pfizer | Phase 1 | 32 |
| ixabepilone + lapatinib ditosylate | Bristol Myers Squibb | Phase 1 | 32 |
| carboplatin + irinotecan hydrochloride | Bristol Myers Squibb | Phase 1 | 32 |
| intoplicine | Sanofi | Phase 1 | 32 |
| apomine | Sanofi | Phase 1 | 32 |
| apomine | Sanofi | Phase 1 | 32 |
Other Products from Nektar Therapeutics
NKTR-102 + Eribulin + Ixabepilone + Vinorelbine + Gemcitabine + Paclitaxel + Docetaxel + Nab-paclitaxelPhase 3
72
NKTR-181 BID tablets + Placebo to match NKTR-181 BID tabletsPhase 3
72
NKTR-102 + Treatment of Physician's Choice (TPC)Phase 3
72
NKTR-181 BID tabletsPhase 3
72
NKTR-255 at 1.5 ยตg/kg + NKTR-255 at 3.0 ฮผg/kg + NKTR-255 at 3.0/6.0 ฮผg/kgPhase 2/3
60